C

Canadian Phase Onward | Toronto, Canada

Research site
(Unclaimed)
Location
2 Champagne Drive, Unit A3, Toronto, Ontario, Canada

Site insights

Top conditions

Top treatments

Retatrutide
Olezarsen
ISIS 678354
LY3437943
ACT-132577
Firibastat
AD109
Aprocitentan
Survodutide
JNJ-64565111

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 13 total trials

A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.

Enrolling
Severe Hypertriglyceridemia
Drug: Olezarsen

The purpose of the study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from bas...

Active, not recruiting
Severe Hypertriglyceridemia
Drug: Placebo
Drug: Olezarsen
Locations recently updated

The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master pr...

Enrolling
Overweight
Knee Pain Chronic
Drug: Retatrutide
Drug: Placebo
Locations recently updated

The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight a...

Enrolling
Overweight
Obesity
Drug: Retatrutide
Drug: Placebo

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Tirzepatide
Drug: Dulaglutide

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling
Obesity
Drug: Placebo
Drug: survodutide

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Ob...

Enrolling
OSA
Drug: Placebo
Drug: AD109

The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the t...

Active, not recruiting
Obesity
Metabolic Syndrome
Drug: INV-202
Drug: Placebo

Trial sponsors

Lilly logo
Ionis Pharmaceuticals logo
J
A
Apnimed logo
Boehringer Ingelheim logo
Idorsia Pharmaceuticals logo
I
Q

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems